Market Size of ELISpot And FluoroSpot Assay Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 13.30 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
ELISpot and Fluorospot Assay Market Analysis
The ELISpot and FluoroSpot assay market is expected to register a CAGR of 13.3% during the forecast period.
- The COVID-19 pandemic significantly impacted healthcare systems worldwide, including the ELISpot and FluoroSpot assay markets. A 2020 article by Medtech suggested a link between antibody titers and T-cell responsiveness in COVID-19. The strongest T-cell response was observed in three individuals (C4, C5, and C7), with the lowest antibody response in COVID-19 patients, as measured by the FluoroSpot assay. ELISpot and FluoroSpot assays are commonly used to assess SARS-CoV-2-specific T- and B-cell immunity in COVID-19 patients. However, since COVID-19 cases declined last year, the market has reported a slight decline. Nevertheless, the market is expected to show a stable growth rate during the forecast period.
- The ELISpot and FluoroSpot assay market is expected to grow due to several factors. Firstly, rising vaccine research to tackle drug-resistant strains, the growing global occurrence of chronic illnesses, and technological innovations in ELISpot and FluoroSpot analyzers and assay kits are expected to drive market growth. ELISpot is a critical tool in vaccine development for various illnesses, including acquired immunodeficiency syndrome (AIDS), tuberculosis, malaria, cancer, and flu. The ELISpot test is widely utilized in clinical studies to evaluate vaccines. In a June 2021 article published in BMC Infectious Diseases Journal, the FluoroSpot assay based on the ELISpot was more accurate than enzyme-linked immunoassay (ELISA) or flow cytometry (FCM). Therefore, these assays are given priority to ensure precision in research diagnostics.
- The prevalence of chronic diseases is also expected to boost the market growth of ELISpot and FluoroSpot assays. According to the Canadian Cancer Statistics November 2021 report, an estimated 2 in 5 Canadians were likely to be diagnosed with cancer in their lifetime. An estimated 229,200 Canadians are predicted to have been diagnosed with cancer in 2021. Furthermore, non-communicable diseases (NCDs) kill 41 million people globally each year, equivalent to 71% of all deaths, according to an April 2021 update by the World Health Organization (WHO). More than 15 million people die from NCDs between the ages of 30 and 69 years, with 85% of these premature deaths occurring in low- and middle-income countries. Consequently, the increasing prevalence of chronic diseases is expected to increase the utility of ELISpot and FluroSpot assays for diagnosis purposes, propelling the market growth.
- The strategic initiatives adopted by key players, such as product launches, approvals, partnerships, and research studies, are also expected to drive market growth. For instance, in April 2021, Ardigen and ImmuMap launched a research collaboration focused on identifying T-cell receptors (TCRs) reactive to tumor-associated neoantigens. The collaboration involves ELISpot assays, next-generation sequencing (NGS), MHC multimer labeling and sorting, and 10x Genomics Single Cell Immune Profiling. Such developments are expected to spur innovation in the assays and ultimately augment market growth.
- In conclusion, the ELISpot and FluoroSpot market is expected to witness tremendous growth over the forecast period due to factors such as the rising prevalence of chronic diseases and technological advancements by key players. However, the availability of alternative detection technologies is likely to impede market growth.
ELISpot and Fluorospot Assay Industry Segmentation
As per the scope of the report, FluroSpot and ELISpot are commonly used with fluorophores marked detection reagents for the realistic analysis of the immune system at the single-cell level. The FluoroSpot assay integrates ELISpot's sensitivity with the ability to concurrently analyze multi-analyte secretion, allowing cell population studies with different operational characteristics.
The ELISpot and FluoroSpot assay market is segmented by product (analyzers, assay kits, and ancillary products), application (research (vaccine development, clinical trials, and cancer research), and diagnostics (infectious disease and transplants)), end user (hospitals & clinical labs, biopharmaceutical companies, and research institutes), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD million) for the above segments.
By Product | |
Analyzers | |
Assay kits | |
Ancillary Products |
By End-User | |
Hospitals & Clinical labs | |
Biopharmaceutical Company | |
Research Institutes |
By Application | |||||
| |||||
|
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
ELISpot And FluoroSpot Assay Market Size Summary
The ELISpot and FluoroSpot assay market is poised for significant growth, driven by advancements in vaccine research and the increasing prevalence of chronic diseases. These assays are crucial in vaccine development and are extensively used in clinical studies to evaluate immune responses to various diseases, including cancer and infectious diseases. The market's expansion is further supported by technological innovations in assay kits and analyzers, which enhance the precision and accuracy of diagnostic research. Despite the initial impact of the COVID-19 pandemic, which temporarily affected market dynamics, the sector is expected to stabilize and grow steadily over the forecast period. Strategic initiatives by key industry players, such as product launches and research collaborations, are also anticipated to contribute to market growth.
North America is expected to lead the ELISpot and FluoroSpot assay market, fueled by a high incidence of cancer and infectious diseases in the region. The demand for these assays is bolstered by technological advancements in test kits and analyzers, which improve diagnostic capabilities. The market is characterized by a consolidated landscape, with major players holding significant market shares and actively engaging in mergers, acquisitions, and product innovations to strengthen their positions. The assay kits segment remains dominant due to their widespread application in life science research, drug development, and environmental monitoring, further propelling market growth during the forecast period.
ELISpot And FluoroSpot Assay Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Incidence of Chronic Diseases
-
1.2.2 Technological Breakthroughs in Test Kits and analyzers for ELISpot and FluoroSpot
-
-
1.3 Market Restraints
-
1.3.1 Availability of alternative detection technologies
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product
-
2.1.1 Analyzers
-
2.1.2 Assay kits
-
2.1.3 Ancillary Products
-
-
2.2 By End-User
-
2.2.1 Hospitals & Clinical labs
-
2.2.2 Biopharmaceutical Company
-
2.2.3 Research Institutes
-
-
2.3 By Application
-
2.3.1 Research
-
2.3.1.1 Vaccine Development
-
2.3.1.2 Clinical Trials
-
2.3.1.3 Cancer Research
-
-
2.3.2 Diagnostics
-
2.3.2.1 Infectious Disease
-
2.3.2.2 Transplants
-
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle-East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle-East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
ELISpot And FluoroSpot Assay Market Size FAQs
What is the current ELISpot And FluoroSpot Assay Market size?
The ELISpot And FluoroSpot Assay Market is projected to register a CAGR of 13.30% during the forecast period (2024-2029)
Who are the key players in ELISpot And FluoroSpot Assay Market?
Becton, Dickinson and Company, U-CyTech biosciences, Cellular Technologies Limited (CTL), Mabtech AB and Abcam are the major companies operating in the ELISpot And FluoroSpot Assay Market.